Surveillance of SARS-CoV-2 immunogenicity: loss of immunodominant HLA-A*02-restricted epitopes that activate CD8+ T cells

Front Immunol. 2023 Nov 3:14:1229712. doi: 10.3389/fimmu.2023.1229712. eCollection 2023.

Abstract

Introduction and methods: In this present work, coronavirus subfamilies and SARS-CoV-2 Variants of Concern (VOCs) were investigated for the presence of MHC-I immunodominant viral peptides using in silico and in vitro tools.

Results: In our results, HLA-A*02 haplotype showed the highest number of immunodominant epitopes but with the lowest combined prediction score. Furthermore, a decrease in combined prediction score was observed for HLA-A*02-restricted epitopes when the original strain was compared to the VOCs, indicating that the mutations on the VOCs are promoting escape from HLA-A2-mediated antigen presentation, which characterizes a immune evasion process. Additionally, epitope signature analysis revealed major immunogenic peptide loss for structural (S) and non-structural (ORF8) proteins of VOCs in comparison to the Wuhan sequence.

Discussion: These results may indicate that the antiviral CD8+ T-cell responses generated by original strains could not be sufficient for clearance of variants in either newly or reinfection with SARS-CoV-2. In contrast, N epitopes remain the most conserved and reactive peptides across SARS-CoV-2 VOCs. Overall, our data could contribute to the rational design and development of new vaccinal platforms to induce a broad cellular CD8+ T cell antiviral response, aiming at controlling viral transmission of future SARS-CoV-2 variants.

Keywords: CD8+ T cells; HLA-A2; SARS-CoV-2; immunoinformatics; peptide microarray.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents
  • CD8-Positive T-Lymphocytes*
  • COVID-19*
  • Epitopes, T-Lymphocyte / genetics
  • HLA-A2 Antigen
  • Histocompatibility Antigens Class I
  • Humans
  • Peptides
  • SARS-CoV-2

Substances

  • Epitopes, T-Lymphocyte
  • Histocompatibility Antigens Class I
  • HLA-A2 Antigen
  • Peptides
  • Antiviral Agents

Supplementary concepts

  • SARS-CoV-2 variants

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by Fundação de Amparo à Pesquisa de Minas Gerais (FAPEMIG, APQ-01499-21), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq MCTI/CNPQ/Universal 14/2014 – A Tier; process# 458134/2014-7) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES). FF, EB-S, and JC-d-R received PQ fellowships from CNPq and Pró-Reitoria de Pesquisa da Universidade Federal de Minas Gerais (PRPq).